CBD research - A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis

2013: A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis

To investigate the ability of Sativex to relieve central neuropathic pain in multiple sclerosis subjects.

Detailed Description

Multiple sclerosis subjects with a clinical diagnosis of central neuropathic pain entered a seven to ten day baseline period, followed by a four week double blind, randomised, parallel group comparison of Sativex, with placebo. The study medication was self-titrated to symptom resolution or maximum tolerated or allowed dose. Visits occurred at the end of weeks one and four (end of the study) or earlier if they withdrew. A follow-up visit occurred 30 - 40 days after completion or withdrawal.

Contact us - Contact

Contact us for more info & pricing

Fields marked with * are required